A recent study reported the first clinical results using BKM 120—an oral pan class I PI3K inhibitor with promising activity in several cancers—as a form of monotherapy in a cohort of 42 patients with pretreated advanced ESCC; of the 42 patients enrolled, 20 had stable disease and 2 had confirmed partial responses [79]. The gene discussed is PIK3CA; the disease is cancer.